Our Life Sciences group is a multi-disciplinary team of more than 90 lawyers drawn from across our global network.
We have a reputation for far-sighted advice to some of the world’s leading life science companies and are described as "an efficient and client-oriented team" in Chambers Global 2010 Life Sciences edition.
Our support for pharmaceuticals, biotech, medical devices, nursing homes and other healthcare-related companies, as well as financial institutions operating in the sector, covers the spectrum: mergers and acquisitions (M&A), commercial transactions, including licensing and collaborations, intellectual property (IP) protection and patent disputes, capital markets and finance, regulatory and private equity.
Our international network enables us to deploy the skills of market-leading experts in a number of jurisdictions and we are well placed to advise on cross-border work, both contentious and non-contentious.
News & insights
News: 18 SEPTEMBER 2020
We have advised Apax Partners and its portfolio company Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), on the acquisition of the…Read more
Publications: 29 JULY 2020
Setting the stage Since long, discussions in Belgium have been ongoing as to who needs to prove that a patient was sufficiently informed about his/her treatment and its potential complications. With…Read more
News: 20 JULY 2020
An A&O team comprising UK, German, U.S. and Dutch lawyers is advising GlaxoSmithKline (GSK) on its strategic collaboration with German biotech company CureVac for the research, development and…Read more
Publications: 03 JUNE 2020
The German Foreign Direct Investment (FDI) screening rules were amended, bringing important parts of the health care sector under the regime applicable to critical infrastructure. Some, but not all,…Read more